Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Major Apple Shareholder Warren Buffett Trims Position

Robert Sasse by Robert Sasse
November 21, 2025
in Analysis, Market Commentary, Nasdaq, S&P 500, Tech & Software
0
Apple Stock
0
SHARES
16
VIEWS
Share on FacebookShare on Twitter

While Apple continues to deliver robust financial performance, its share price remains stubbornly range-bound. As retail investors await a fresh catalyst, prominent institutional players are making decisive moves that are causing unease on the trading floor. The most significant development comes from Warren Buffett’s Berkshire Hathaway, sparking debate over whether this is a temporary pause or the start of a more substantial market correction.

Institutional Selling Pressure Mounts

Market sentiment is currently facing headwinds from the activities of so-called “smart money” investors. Recent filings confirm that Berkshire Hathaway disposed of approximately 42 million Apple shares during the third quarter. This transaction represents a substantial 15 percent reduction in their holdings.

Although Apple maintains its status as the largest position within Berkshire’s investment portfolio, this sale continues a clear pattern of divestment. Buffett isn’t acting in isolation—several other major funds have similarly scaled back their exposure to the technology giant in the most recent quarter. This institutional selling is noticeably dampening investor enthusiasm.

Technical Picture Shows Weakness

From a technical analysis perspective, the stock appears vulnerable, struggling to decisively break through key resistance levels. What’s particularly frustrating for shareholders is that the company’s fundamentally strong financial results are failing to translate into price appreciation.

Should investors sell immediately? Or is it worth buying Apple?

  • Revenue Growth Overlooked: Neither the 8.7 percent revenue increase nor earnings that surpassed expectations have provided sustainable upward momentum.
  • Shift in Market Focus: Investors are largely ignoring solid fundamentals and instead concentrating on the selling activity of major stakeholders.
  • Momentum Indicators: The stock’s advance has stalled, with weekly charts beginning to show early warning signs of negative divergence.

The equity remains trapped within a narrow trading range characterized by indecision. Until the share price can overcome these technical barriers and prominent sellers cease their activity, consolidation appears to be the most likely near-term scenario.

Analyst Maintains Cautious Stance

Adding to the mixed environment, a recent assessment from Swiss banking giant UBS offers little hope for immediate price breakthroughs. Analyst David Vogt reaffirmed his “Neutral” rating on the stock.

While Vogt acknowledges that availability of new iPhone models is gradually improving, waiting times remain elevated. For UBS analysts, this development isn’t sufficient to justify a more bullish position. The market appears to have already priced in this cautious approach, with shares continuing to trade around €229.40—well below their 52-week peak.

Ad

Apple Stock: Buy or Sell?! New Apple Analysis from March 25 delivers the answer:

The latest Apple figures speak for themselves: Urgent action needed for Apple investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Apple: Buy or sell? Read more here...

Tags: Apple
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026
Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock
AI & Quantum Computing

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
Next Post
Asml Stock

ASML Shares Face Sudden Market Pressure

Bitcoin Stock

Bitcoin Plummets to $82,000 as Macroeconomic Pressures Mount

Lockheed Stock

Lockheed Martin Shares Decline Amid Major Defense Contract Wins

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com